Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Longeveron
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
May 26, 2026
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
May 25, 2026
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 25, 2026
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
May 24, 2026
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
May 21, 2026
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
May 16, 2026
Longeveron Announces Closing of Private Placement of up to $30 Million
May 16, 2026
Longeveron Announces Private Placement of up to $30 Million
May 16, 2026
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
January 29, 2026
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
January 26, 2026